Condition: Psoriatic Arthritis · Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical study, consisting of a 4-week screening period, a 24-week core treatment period, a 24-week maintenance treatment period, and an 8-week safety follow-up period. It is planned to include 150 adult subjects with psoriatic arthritis.
This description comes directly from the study's public registry record.
Su Zhang, M.M · 0518-82342973 · su.zhang.sz3@hengrui.com
Always discuss trial participation with your own doctor first.
| Huashan Hospital of the Shanghai FuDan University | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06640257